![]() |
Trials |
A phase Ia/Ib, first-in-human, open label, multicentre, dose-escalation and dose-expansion study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumoursCancer type: Solide tumores Phase: I Principal Investigator: Yachnin Jeffrey Country: SE Keywords: Sweden, Stockhom, Nano, NZ-DTX Depot, Nano-zolid Status: Open for inclusion |